Given that IgA deficiency predisposes individuals to IBD [50] and exacerbates the severity of DSS-induced colitis in mice [18], it has been proposed that targeting the PHD/HIF-1α axis with the PHD inhibitor roxadustat, the first HIF stabilizer approved for the clinical treatment of renal anemia [33], may modulate IgA responses and alleviate experimental intestinal disease. Here, HIF1A is linked to intestinal disorder.